Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults (EXSFN)
19 giugno 2026 aggiornato da: Hashim Islam, University of British Columbia
Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study
The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion.
The interventional periods will be separated by a minimum 1 week washout period.
One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite).
Another intervention will consist of 4 days of daily supervised treadmill running.
The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions.
The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training.
Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected.
Blood samples will be analyzed for metabolic and inflammatory markers.
Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods.
Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires.
The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.
Panoramica dello studio
Stato
Reclutamento
Tipo di studio
Interventistico
Iscrizione (Stimato)
20
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Hashim Islam Principle Investigator, Ph.D
- Numero di telefono: 250-807-9122
- Email: hashim.islam@ubc.ca
Luoghi di studio
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1V 1V7
- Reclutamento
- Reichwald Health Sciences Centre
-
Contatto:
- Sean McIntyre
- Numero di telefono: 2505757528
- Email: smcint04@student.ubc.ca
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Sì
Descrizione
Inclusion Criteria:
- aged between 18 and 35 years
- not a current smoker
- physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)
Exclusion Criteria:
- a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)
- currently following a ketogenic diet
- body mass index (BMI) over 30 kg/m2
- unable to read or communicate in English
- having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks
- having donated more than 0.5 L of blood within the last 4 weeks
- currently pregnant
- have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Sulforaphane Supplementation Only
In this intervention, participants will consume commercially available broccoli sprout extract capsules daily for 4 days (20 mg/day) .
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
|
|
Comparatore attivo: Exercise Only
In this intervention, participants will complete supervised exercise sessions daily for 4 days.
The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace.
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.
|
|
Sperimentale: Sulforaphane Supplementation and Exercise
In this intervention, participants will consume commercially available broccoli sprout extract tablets daily for 4 days.
In addition, participants will complete supervised exercise sessions daily for 4 days.
The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace.
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in peripheral blood mononuclear cell oxygen consumption rate
Lasso di tempo: 0-4 days
|
OCR will be measured using a Seahorse Analyzer before and after each 4-day intervention
|
0-4 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
TNF-alpha secretion from LPS-stimulated whole blood
Lasso di tempo: 0-4 days
|
TNF-alpha secretion from LPS-stimulated whole blood will be measured via ELISA before and after each 4-day period
|
0-4 days
|
|
Change in % of classical monocytes before and after the 6-week intervention
Lasso di tempo: 0-4 days
|
The % of classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in % of intermediate monocytes before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
The % of intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in % of non-classical monocytes before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
The % of non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in TLR-4 expression on classical monocytes before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
TLR-4 expression on classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
|
0-4 days
|
|
Change in TLR-4 expression on intermediate monocytes before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
TLR-4 expression on intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
|
0-4 days
|
|
Change in TLR-4 expression on non-classical monocytes before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
TLR-4 expression on non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in white blood cell counts before and after the 4-day intervention
Lasso di tempo: 0-4 days
|
White blood cell counts will be measured using a hematology analyzer at baseline and after the 4-day intervention
|
0-4 days
|
|
TNF-alpha secretion from PolyIC-stimulated whole blood
Lasso di tempo: 0-4 days
|
TNF-alpha secretion from PolyIC-stimulated whole blood will be measured via ELISA before and after each 4-day period
|
0-4 days
|
|
Change in peripheral blood mononuclear cell extracellular acidification rate before and after the 4-day period
Lasso di tempo: 0-4 days
|
PBMC ECAR will be measured using a Seahorse Analyzer at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in PBMC mitotracker green staining before and after the 4-day period
Lasso di tempo: 0-4 days
|
PBMC mitotracker green will be measured using flow cytometry before and after the 4-day intervention period
|
0-4 days
|
|
Change in PBMC mitoSOX red staining before and after the 4-day period
Lasso di tempo: 0-4 days
|
PBMC mitoSOX red will be measured using flow cytometry before and after the 4-day intervention period
|
0-4 days
|
|
Change in PBMC mitochondrial respiration before and after the 4-day intervention period
Lasso di tempo: 0-4 days
|
PBMC mitochondrial respiration will be measured using high-resolution respirometry before and after the 4-day period
|
0-4 days
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 marzo 2026
Completamento primario (Stimato)
1 dicembre 2027
Completamento dello studio (Stimato)
1 giugno 2028
Date di iscrizione allo studio
Primo inviato
19 giugno 2026
Primo inviato che soddisfa i criteri di controllo qualità
19 giugno 2026
Primo Inserito (Effettivo)
25 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
25 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
19 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- H25-03273
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
IPD will not be shared to ensure the privacy and confidentiality of participants, in accordance with ethical guidelines and data protection regulations.
Additionally, this was not included in the informed consent, which did not cover data sharing or address potential risks of re-identification.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .